2023 Program Provided Hands-On Optometry Student Learning in ECP Practices
SAN RAMON, CALIF., September 28, 2023—CooperVision’s 2023 Myopia Immersion Experience has equipped a group of passionate optometrists in training to explore and better navigate managing myopia in the real world. The program, known for its rigorous selection process, welcomed rising second-year optometry students from across the United States. Participants for the 2023 program included Susanna Tan and Taea Jackson from the University of California Berkeley Herbert Wertheim School of Optometry & Vision Science, and De’ja Montgomery and Lauren Martinez from the University of Houston College of Optometry.
Spanning eight-weeks this summer, the hands-on initiative placed students within multiple clinical practices including those of Elsa Pao, OD, Eileen Lo, OD, at East Bay Vision Center, and Aamena Kazmi, OD, at Bellaire Family Eye Care. Responsibilities included teaching age-appropriate children how to apply and remove MiSight® 1 day* contact lenses, educating families about myopia control and management, and assisting with comprehensive eye exams.
“I thoroughly enjoyed working with my intern over the summer and thank CooperVision for the opportunity to collaborate with one of the brightest minds in the future of optometry,” said Dr. Lo. “Our partnership was gratifying, and I learned a lot from her as well. It was an enriching learning experience for both of us!”
Now prescribed in more than 30 countries, MiSight® 1 day is the first and only± FDA-approved* soft contact lens to slow the progression of myopia in children aged 8-12 at the initiation of treatment.† The company also offers orthokeratology contact lenses for myopia management in the U.S.. For more information, please visit www.coopervision.com.
1 Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8)556-567.
± Only FDA approved soft contact lens designed for myopia control in the U.S.
* U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1-day lens over a 3-year period.
# # #
About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com
Media Contact
Laura DiCaprio, Senior Counselor
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-545-1815